latest update:
[TrialBase DB]

trial summary · NCT07818369

Synbiotic LA-5 and Agave Inulin for Mild Cognitive Impairment

Effect of a Symbiotic (Lactobacillus Acidophilus LA-5 and Agave Inulin) on Mild Cognitive Impairment in Older Adults of the Defense Medical Specialties Unit

Trial record from the TrialBase DB dataset, status RECRUITING, condition Cognitive Impairment, sponsored by Anahuac University. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07818369phase —enrollment 20start 2026-12-31

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This pilot randomized, double-blind, crossover clinical trial will evaluate the effect of a synbiotic containing Lactobacillus acidophilus LA-5 and agave inulin on mild cognitive impairment (MCI) in adults aged 60-75 years attending the Defense Medical Specialties Unit. Forty participants with MCI will be randomized into two groups of 20 participants. The intervention will consist of daily administration of L. acidophilus LA-5 (4 × 10⁹ CFU), 7 g of agave inulin, and almond powder for 12 weeks, while the control group will receive almond powder as the vehicle. After a two-week washout period, participants will cross over to the alternate intervention for an additional 12 weeks. Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), Memory Alteration Test (M@T), and Mini-Mental State Examination (MMSE). Secondary assessments will explore potential mechanisms of the microbiota-gut-brain axis by measuring fecal L. acidophilus LA-5 and butyrate, as well as serum BDNF and inflammatory biomarkers including IL-1β, IL-6, IL-10, and TNF-α. The study aims to determine whether synbiotic supplementation improves cognitive performance in older adults with MCI and whether these changes are accompanied by modifications in gut microbial activity, short-chain fatty acid production, neurotrophic signaling, and systemic inflammation.

Source record: https://clinicaltrials.gov/study/NCT07818369

Facts

registry idNCT07818369
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionCognitive Impairment
sponsorAnahuac University
sponsor classOTHER
enrollment20
start date2026-12-31
primary completion2027-11-01
completion2027-11-30
results postednot reported

Conditions

  • Cognitive Impairment

Interventions

  • Synbiotic (Lactobacillus acidophilus LA-5 and Agave Inulin) Intervention Type:

Countries

  • Mexico

Intervention types: DIETARY_SUPPLEMENT

Work with this record